Clinical summary
Summary
This non-randomised, open-label study has six experimental arm all evaluating different treatment regimens. In Experimental Arm A, participants will receive a treatment regimen of Teclistamab + Daratumumab + Pomalidomide. In Experimental Arm B, participants will receive Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles). In Experimental Arm C, participants will receive Teclistamab + Nirogacestat. In Experimental Arm D, participants will receive Teclistamab + Lenalidomide. In Experimental Arm E, participants will receive Teclistamab + Daratumumab + Lenalidomide. In Experimental Arm F, participants will receive Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles).Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Janssen Research & Development, LLC
Scientific Title
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma